8-K current report · filed Nov 17, 2026

Aldeyra Therapeutics, Inc. (ALDX) 8-K Current Report: November 17, 2026

Item 3.01ALDX overview

Short answer

Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K current report with the SEC on November 17, 2026 reporting Item 3.01 (Notice of Delisting). Nasdaq bid-price deficiency after 30 consecutive business days below the $1.00 minimum.

  • This filing includes Item 3.01, an item that often signal trouble.

Why these 8-K items matter →

Aldeyra Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 3.01 · Notice of Delisting

  • Nasdaq bid-price deficiency after 30 consecutive business days below the $1.00 minimum
  • No immediate delisting, Nasdaq listing remains effective
  • Initial compliance deadline: May 17, 2027, requiring at least $1.00 closing bid for 10 consecutive business days
  • Potential second 180-day grace period, contingent on market-value and other listing requirements
  • Delisting risk may increase trading disruption, liquidity pressure and investor concern if compliance is not restored

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aldeyra Therapeutics, Inc. 8-K filings

Get the next ALDX 8-K as it lands

Follow ALDX for push alerts, or ask the research agent what this filing means.